The label for Simlandi (adalimumab-aaty) will include a new boxed warning, effective 2025-12-22. This warning highlights the significant risks of serious infections and malignancy associated with adalimumab products, including Simlandi, which may lead to hospitalization or death.
Boxed Warning Details
The boxed warning states: "WARNING: SERIOUS INFECTIONS and MALIGNANCY SERIOUS INFECTIONS Patients treated with adalimumab products, including SIMLANDI, are at increased risk for developing serious infections that may lead to hospitalization or death [see Warnings and Precautions]."
Background
Simlandi is an adalimumab product. Other adalimumab products include Humira, Hulio, Yusimry, Yuflyma, Idacio, Adalimumab-ryvk, Amjevita, Adalimumab-adbm, Cyltezo, Hadlima, Adalimumab-bwwd, Hyrimoz, Adalimumab-fkjp, Adalimumab-aqvh, Adalimumab-aacf, and Adalimumab-atto.
What this means
The addition of a boxed warning to the Simlandi label emphasizes the critical importance for healthcare providers to counsel patients about the potential for serious infections and malignancy. Clinicians should carefully assess patient risk factors and monitor for signs and symptoms of these adverse events during treatment with Simlandi or other adalimumab products, as these risks may lead to hospitalization or death.
Source
This information is based on a label revision for Simlandi (adalimumab-aaty) from the FDA, effective 2025-12-22. The details are available on dailymed.nlm.nih.gov.